Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
AbbVie Analyst Ratings and Price Targets | NYSE:ABBV | Benzinga
AbbVie Inc has a consensus price target of $203.5 based on the ratings of 32 analysts. The high is $250 issued by Morgan Stanley on April 28, 2025. The low is $150 issued by Deutsche Bank on November 9, 2023. The 3 most-recent analyst ratings were released by Citigroup, Guggenheim, and Raymond James on May 14, 2025, April 29, 2025, and April 28, 2025, respectively. With an average price target of $216 between Citigroup, Guggenheim, and Raymond James, there's an implied 11.98% upside for AbbVie Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Guggenheim
Raymond James
Evercore ISI Group
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for AbbVie
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | 6.28% | Citigroup | Geoff Meacham63% | $210 → $205 | Downgrade | Buy → Neutral | Get Alert |
| 04/29/2025 | Buy Now | 11.98% | Guggenheim | Vamil Divan73% | $214 → $216 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 17.68% | Raymond James | Gary Nachman60% | $220 → $227 | Maintains | Outperform | Get Alert |
| 04/28/2025 | Buy Now | 6.28% | Evercore ISI Group | Gavin Clark-Gartner40% | $204 → $205 | Maintains | Outperform | Get Alert |
| 04/28/2025 | Buy Now | 29.61% | Morgan Stanley | Terence Flynn65% | $241 → $250 | Maintains | Overweight | Get Alert |
| 04/22/2025 | Buy Now | 8.87% | Cantor Fitzgerald | Carter Gould55% | → $210 | Initiates | → Overweight | Get Alert |
| 04/17/2025 | Buy Now | 10.94% | Guggenheim | Vamil Divan73% | $214 → $214 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2025 | Buy Now | 24.94% | Morgan Stanley | Terence Flynn65% | $239 → $241 | Maintains | Overweight | Get Alert |
| 04/08/2025 | Buy Now | 0.58% | Goldman Sachs | Asad Haider 57% | → $194 | Assumes | → Neutral | Get Alert |
| 03/05/2025 | Buy Now | 24.42% | Wells Fargo | Mohit Bansal67% | $210 → $240 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | 15.61% | B of A Securities | Tim Anderson65% | $200 → $223 | Maintains | Neutral | Get Alert |
| 02/03/2025 | Buy Now | 11.46% | Citigroup | Geoff Meacham63% | $205 → $215 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 12.5% | Truist Securities | Srikripa Devarakonda44% | $211 → $217 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | -1.5% | UBS | Navin Jacob65% | $181 → $190 | Maintains | Neutral | Get Alert |
| 02/03/2025 | Buy Now | 8.87% | Wells Fargo | Mohit Bansal67% | $195 → $210 | Maintains | Overweight | Get Alert |
| 02/03/2025 | Buy Now | 23.9% | Morgan Stanley | Terence Flynn65% | $224 → $239 | Maintains | Overweight | Get Alert |
| 02/03/2025 | Buy Now | 14.05% | Raymond James | Gary Nachman60% | $218 → $220 | Reiterates | Outperform → Outperform | Get Alert |
| 02/03/2025 | Buy Now | 10.94% | Guggenheim | Vamil Divan73% | $212 → $214 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 11.46% | BMO Capital | Evan David Seigerman52% | $208 → $215 | Maintains | Outperform | Get Alert |
| 01/28/2025 | Buy Now | 6.28% | Citigroup | Geoff Meacham63% | $215 → $205 | Maintains | Buy | Get Alert |
| 01/17/2025 | Buy Now | 9.91% | Guggenheim | Vamil Divan73% | $221 → $212 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 9.39% | Truist Securities | Srikripa Devarakonda44% | $215 → $211 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 14.05% | Piper Sandler | Christopher Raymond55% | $212 → $220 | Maintains | Overweight | Get Alert |
| 12/10/2024 | Buy Now | -0.98% | B of A Securities | Tim Anderson65% | → $191 | Reinstates | → Neutral | Get Alert |
| 11/22/2024 | Buy Now | 6.8% | Leerink Partners | David Risinger72% | → $206 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/15/2024 | Buy Now | 6.28% | Wolfe Research | Alexandria Hammond49% | → $205 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | 3.69% | JP Morgan | Chris Schott60% | $210 → $200 | Maintains | Overweight | Get Alert |
| 11/12/2024 | Buy Now | 11.46% | Citigroup | Geoff Meacham63% | $226 → $215 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 7.83% | BMO Capital | Evan David Seigerman52% | $228 → $208 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 16.13% | Morgan Stanley | Terence Flynn65% | $231 → $224 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 14.57% | Guggenheim | Vamil Divan73% | $212 → $221 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | — | Argus Research | David Toung68% | — | Upgrade | Hold → Buy | Get Alert |
| 10/31/2024 | Buy Now | 18.2% | BMO Capital | Evan David Seigerman52% | $220 → $228 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 17.17% | Citigroup | Geoff Meacham63% | $215 → $226 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | 3.69% | UBS | Navin Jacob65% | $195 → $200 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 19.76% | Morgan Stanley | Terence Flynn65% | $218 → $231 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 11.46% | Citigroup | Andrew Baum70% | $170 → $215 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 1.09% | B of A Securities | Geoff Meacham63% | $185 → $195 | Maintains | Neutral | Get Alert |
| 10/17/2024 | Buy Now | 14.05% | BMO Capital | Evan David Seigerman52% | $214 → $220 | Maintains | Outperform | Get Alert |
| 10/17/2024 | Buy Now | 5.24% | Bernstein | Aaron Gal54% | → $203 | Initiates | → Market Perform | Get Alert |
| 10/10/2024 | Buy Now | 11.46% | Truist Securities | Srikripa Devarakonda44% | $210 → $215 | Maintains | Buy | Get Alert |
| 10/09/2024 | Buy Now | 1.09% | UBS | Navin Jacob65% | $185 → $195 | Maintains | Neutral | Get Alert |
| 10/07/2024 | Buy Now | 9.91% | Barclays | Carter Gould55% | $200 → $212 | Maintains | Overweight | Get Alert |
| 10/07/2024 | Buy Now | 16.65% | TD Cowen | Steve Scala67% | $195 → $225 | Maintains | Buy | Get Alert |
| 08/23/2024 | Buy Now | 8.35% | Piper Sandler | Christopher Raymond55% | $196 → $209 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 13.02% | Morgan Stanley | Terence Flynn65% | $211 → $218 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | 3.69% | Cantor Fitzgerald | Louise Chen57% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/26/2024 | Buy Now | -4.09% | UBS | Navin Jacob65% | $172 → $185 | Maintains | Neutral | Get Alert |
| 07/26/2024 | Buy Now | 3.69% | Cantor Fitzgerald | Louise Chen57% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/26/2024 | Buy Now | 8.87% | Truist Securities | Robyn Karnauskas53% | $195 → $210 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2024 | Buy Now | 6.28% | Wells Fargo | Mohit Bansal67% | $200 → $205 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | 3.69% | Barclays | Carter Gould55% | $187 → $200 | Maintains | Overweight | Get Alert |
| 07/25/2024 | Buy Now | 8.87% | JP Morgan | Chris Schott60% | $190 → $210 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | 10.94% | BMO Capital | Evan David Seigerman52% | $180 → $214 | Maintains | Outperform | Get Alert |
| 07/11/2024 | Buy Now | 1.61% | Morgan Stanley | Terence Flynn65% | $191 → $196 | Maintains | Overweight | Get Alert |
| 07/09/2024 | Buy Now | 3.69% | Cantor Fitzgerald | Louise Chen57% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/02/2024 | Buy Now | -1.5% | Piper Sandler | Christopher Raymond55% | $190 → $190 | Maintains | Overweight | Get Alert |
| 06/20/2024 | Buy Now | 3.69% | Cantor Fitzgerald | Louise Chen57% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 06/18/2024 | Buy Now | -1.5% | Piper Sandler | Christopher Raymond55% | $185 → $190 | Maintains | Overweight | Get Alert |
| 06/05/2024 | Buy Now | -4.09% | HSBC | Rajesh Kumar61% | → $185 | Upgrade | Hold → Buy | Get Alert |
| 05/17/2024 | Buy Now | 3.69% | Cantor Fitzgerald | Louise Chen57% | → $200 | Initiates | → Overweight | Get Alert |
| 04/29/2024 | Buy Now | -3.05% | Barclays | Carter Gould55% | $195 → $187 | Maintains | Overweight | Get Alert |
| 04/29/2024 | Buy Now | -6.68% | BMO Capital | Evan David Seigerman52% | $195 → $180 | Maintains | Outperform | Get Alert |
| 03/27/2024 | Buy Now | 1.09% | Barclays | Carter Gould55% | $185 → $195 | Maintains | Overweight | Get Alert |
| 03/22/2024 | Buy Now | -1.5% | Guggenheim | Vamil Divan73% | $188 → $190 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | -2.02% | Raymond James | Gary Nachman60% | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | 1.09% | Truist Securities | Robyn Karnauskas53% | $180 → $195 | Maintains | Buy | Get Alert |
| 02/05/2024 | Buy Now | 3.69% | Wells Fargo | Mohit Bansal67% | $180 → $200 | Maintains | Overweight | Get Alert |
| 02/05/2024 | Buy Now | -2.02% | Raymond James | Gary Nachman60% | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | 1.09% | BMO Capital | Evan David Seigerman52% | $187 → $195 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | -4.09% | Barclays | Carter Gould55% | $175 → $185 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | — | William Blair | Tim Lugo31% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | -9.27% | Barclays | Carter Gould55% | $170 → $175 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | -6.68% | Wells Fargo | Mohit Bansal67% | $195 → $180 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | -19.12% | HSBC | Rajesh Kumar61% | $167 → $156 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2023 | Buy Now | -10.31% | Goldman Sachs | Chris Shibutani56% | → $173 | Upgrade | Neutral → Buy | Get Alert |
| 12/01/2023 | Buy Now | -6.16% | Raymond James | Gary Nachman60% | $177 → $181 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | -22.24% | Deutsche Bank | James Shin46% | → $150 | Initiates | → Hold | Get Alert |
| 10/30/2023 | Buy Now | 1.61% | Morgan Stanley | Terence Flynn65% | $193 → $196 | Maintains | Overweight | Get Alert |
| 10/30/2023 | Buy Now | -11.87% | Barclays | Carter Gould55% | $160 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/11/2023 | Buy Now | 0.06% | Morgan Stanley | Terence Flynn65% | $189 → $193 | Maintains | Overweight | Get Alert |
| 09/29/2023 | Buy Now | -8.24% | Raymond James | Gary Nachman60% | → $177 | Initiates | → Outperform | Get Alert |
| 07/28/2023 | Buy Now | -11.87% | Piper Sandler | Christopher Raymond55% | $163 → $170 | Maintains | Overweight | Get Alert |
| 07/25/2023 | Buy Now | — | William Blair | Tim Lugo31% | — | Initiates | → Market Perform | Get Alert |
| 07/14/2023 | Buy Now | -13.42% | HSBC | Rajesh Kumar61% | → $167 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | -5.65% | Morgan Stanley | Terence Flynn65% | $182 → $182 | Reiterates | Overweight → Overweight | Get Alert |
| 04/28/2023 | Buy Now | -11.35% | Guggenheim | Vamil Divan73% | $172 → $171 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | -5.65% | Morgan Stanley | Terence Flynn65% | $181 → $182 | Maintains | Overweight | Get Alert |
| 04/28/2023 | Buy Now | 1.09% | Wells Fargo | Mohit Bansal67% | $200 → $195 | Maintains | Overweight | Get Alert |
| 04/13/2023 | Buy Now | -17.05% | Barclays | Carter Gould55% | $155 → $160 | Maintains | Equal-Weight | Get Alert |
| 04/10/2023 | Buy Now | -6.16% | Morgan Stanley | Terence Flynn65% | $178 → $181 | Maintains | Overweight | Get Alert |
| 04/05/2023 | Buy Now | — | Argus Research | Jasper Hellweg68% | — | Downgrade | Buy → Hold | Get Alert |
| 03/01/2023 | Buy Now | -10.83% | Guggenheim | Vamil Divan73% | → $172 | Initiates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | — | Wolfe Research | Tim Anderson65% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 02/10/2023 | Buy Now | -21.2% | UBS | Navin Jacob65% | $150 → $152 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -20.68% | SVB Leerink | David Risinger72% | $135 → $153 | Upgrade | Underperform → Market Perform | Get Alert |
| 02/10/2023 | Buy Now | -20.16% | Atlantic Equities | Steve Chesney53% | $157 → $154 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -7.72% | Morgan Stanley | Terence Flynn65% | $182 → $178 | Maintains | Overweight | Get Alert |
| 02/10/2023 | Buy Now | -15.5% | Piper Sandler | Christopher Raymond55% | $157 → $163 | Maintains | Overweight | Get Alert |
| 02/09/2023 | Buy Now | -6.68% | Truist Securities | Robyn Karnauskas53% | → $180 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for AbbVie (ABBV) stock?
The latest price target for AbbVie (NYSE:ABBV) was reported by Citigroup on May 14, 2025. The analyst firm set a price target for $205.00 expecting ABBV to rise to within 12 months (a possible 6.28% upside). 59 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbbVie (ABBV)?
The latest analyst rating for AbbVie (NYSE:ABBV) was provided by Citigroup, and AbbVie downgraded their neutral rating.
When was the last upgrade for AbbVie (ABBV)?
The last upgrade for AbbVie Inc happened on November 22, 2024 when Leerink Partners raised their price target to $206. Leerink Partners previously had a market perform for AbbVie Inc.
When was the last downgrade for AbbVie (ABBV)?
The last downgrade for AbbVie Inc happened on May 14, 2025 when Citigroup changed their price target from $210 to $205 for AbbVie Inc.
When is the next analyst rating going to be posted or updated for AbbVie (ABBV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating AbbVie (ABBV) correct?
While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a downgraded with a price target of $210.00 to $205.00. The current price AbbVie (ABBV) is trading at is $192.89, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
